Sidoti Research Analysts Increase Earnings Estimates for PRE

Prenetics Global Limited (NASDAQ:PRE) – Equities research analysts at Sidoti lifted their Q3 2026 EPS estimates for Prenetics Global in a research note issued to investors on Wednesday, August 19th. Sidoti analyst A. Hantman now forecasts that the company will post earnings of ($0.65) per share for the quarter, up from their prior estimate of ($0.85). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.28) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.36) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.72) EPS.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.31. The company had revenue of $46.49 million during the quarter, compared to the consensus estimate of $49.85 million. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%.

A number of other research firms have also issued reports on PRE. Benchmark upped their price target on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen lowered Prenetics Global from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Prenetics Global currently has an average rating of “Moderate Buy” and an average target price of $34.25.

Prenetics Global Price Performance

PRE opened at $17.97 on Friday. The firm has a market capitalization of $303.15 million, a price-to-earnings ratio of -4.32 and a beta of 0.26. The company’s 50 day simple moving average is $19.08 and its two-hundred day simple moving average is $18.88. Prenetics Global has a 1-year low of $7.18 and a 1-year high of $23.63.

Institutional Trading of Prenetics Global

Several hedge funds have recently made changes to their positions in the company. State of Wyoming acquired a new stake in shares of Prenetics Global during the 1st quarter worth approximately $48,000. Wells Fargo & Company MN acquired a new position in Prenetics Global in the fourth quarter valued at approximately $47,000. JPMorgan Chase & Co. acquired a new position in Prenetics Global in the third quarter valued at approximately $65,000. Manatuck Hill Partners LLC purchased a new position in Prenetics Global in the fourth quarter worth approximately $170,000. Finally, T3 Companies LLC purchased a new position in Prenetics Global in the fourth quarter worth approximately $170,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

More Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 reported Q2 2026 revenue growth of 288% year over year and raised its FY 2026 revenue guidance to $220–$230 million. Prenetics also initiated FY 2027 revenue guidance of at least $400 million, signaling management expects rapid growth to continue. IM8 Q2 2026 revenue and guidance article
• Positive Sentiment: Actress and producer Lily Collins will become IM8’s first film-and-television global ambassador and a Prenetics shareholder under a multi-year partnership. Her reach of more than 33 million social-media followers is expected to broaden IM8’s exposure, particularly among female consumers, beyond its existing sports-focused ambassador roster. Lily Collins IM8 partnership article
• Positive Sentiment: Management said IM8 has delivered more than 57 million servings, ships approximately 200,000 servings daily across 46 countries, and generated 54% of revenue outside the United States. Prenetics also reported positive consolidated adjusted free cash flow in July and expects to remain positive through the third quarter and beyond.
• Neutral Sentiment: Analyst estimate changes were mixed: Sidoti modestly raised its Q1 2028 EPS forecast to $0.29 but trimmed its FY 2028 estimate to $2.12, while Zacks lowered its FY 2027 EPS estimate to $1.49 from $1.56. The revisions do not materially change the broader growth narrative.
• Negative Sentiment: The elevated 2026–2027 targets are forward-looking and depend on sustained IM8 demand, successful product launches—including hydration and gummies—and effective marketing. Prenetics remains unprofitable, with consensus estimates calling for a current-year loss of $1.28 per share, leaving execution risk significant.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.